MannKind Corp., a biopharmaceutical company, has informed the Connecticut Department of Labor it is laying off 131 workers at its Danbury manufacturing plant, The Associated Press reports.
The cuts are part of 179, or 40 percent of its work force, announced last week by the Valencia, Calif., company. Mannkind is conserving cash as it seeks government approval for its inhaled insulin, Afrezza. The Food and Drug Administration has told MannKind to run additional clinical trials. An analyst has said he does not expect the FDA to take action on Afrezza before 2013.
MannKind’s California offices were closed Monday and a call was not immediately returned.
The company reported a $38.3 million loss in the fourth quarter. Its shares were down 32 cents, or 8 percent, to $3.47 in trading Monday.
